Joanne Ryan
Joanne Ryan is an expert in Neurology at Monash University (Australia). As of October 2026, ScienceLeadR ranks Joanne Ryan in the top 1% of experts worldwide for Dementia, Neurocognitive Disorders and Cognition Disorders. Joanne Ryan has authored 389 publications, the most recent in 2026, and is an investigator in 4 clinical trials. SLR score: 1,424 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Geriatrics - Cardiology - Psychiatry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2008 - 2026
Number : 389
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Multidimensional Aging Trajectories Preceding Cardiovascular Events. PMID 42776539 — quality of life, heart, aging, case-control studies, cardiovascular diseases, aged, frailty | JAMA Cardiol | 2026 | 0 |
| Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. PMID 42670961 — diabetes mellitus, dementia, cardiovascular diseases, drug-related side effects and adverse reactions, atorvastatin | N Engl J Med Top journal | 2026 | 7 |
| Longitudinal Changes in Heart Stress and the Risk for Cardiovascular Disease and Mortality in Older Adults : An Observational Study. PMID 42607310 — mortality, internal medicine, heart, stress, physiological, cardiovascular diseases | Ann Intern Med | 2026 | 1 |
| Associations between serum uric acid levels and risk of dementia in community-dwelling older adults. PMID 42597697 — dementia, uric acid, epidemiology, serum, cognitive dysfunction, biomarkers, cognition disorders, sex | Alzheimers Dement (Amst) | 2026 | 0 |
| P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2- Metastatic Breast Cancer in the USA-A Vodcast. PMID 42560565 — disease-free survival, aromatase, aromatase inhibitors, breast neoplasms, progression-free survival, neoplasms, breast, therapeutics, artificial intelligence | Target Oncol | 2026 | 0 |
Clinical Studies 4
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map